Citius Pharmaceuticals (DB:47N) - Stock Price, News & Analysis

47N Stock Overview

A late-stage biopharmaceutical company, engages in the development and commercialization of critical care products.

47N fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 98.7% below our estimate of its fair value

Earnings are forecast to grow 65.59% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months

Shareholders have been diluted in the past year

Citius Pharmaceuticals, Inc. Competitors

Pierrel

DB:2FJ0

€92.8m

MPH Health Care

DB:93M1

€80.9m

Redx Pharma

DB:0RX

€65.0m

Apontis Pharma

XTRA:APPH

€58.5m

Price History & Performance

Summary of all time highs, changes and price drops for Citius Pharmaceuticals
Historical stock prices
Current Share Price	US$0.49
52 Week High	US$0.93
52 Week Low	US$0.43
Beta	1.68
11 Month Change	-39.55%
3 Month Change	-19.71%
1 Year Change	-40.39%
33 Year Change	-71.83%
5 Year Change	n/a
Change since IPO	-73.64%

Recent updates

Shareholder Returns

	47N	DE Pharmaceuticals	DE Market
7D	-0.2%	1.7%	1.5%
1Y	-40.4%	-15.4%	6.2%

Return vs Industry: 47N underperformed the German Pharmaceuticals industry which returned -15.4% over the past year.

Return vs Market: 47N underperformed the German Market which returned 6.2% over the past year.

Price Volatility

Is 47N's price volatile compared to industry and market?
47N volatility
47N Average Weekly Movement	15.9%
Pharmaceuticals Industry Average Movement	5.3%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.5%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: 47N's share price has been volatile over the past 3 months.

Volatility Over Time: 47N's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2007	22	Leonard Mazur	citiuspharma.com

Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company, engages in the development and commercialization of critical care products. The company's diversified pipeline includes two late-stage product candidates, Mino-Lok and LYMPHIR. The company has enrollment in a Phase 3 pivotal trial of Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections.

Citius Pharmaceuticals, Inc. Fundamentals Summary

How do Citius Pharmaceuticals's earnings and revenue compare to its market cap?
47N fundamental statistics
Market cap	€93.21m
Earnings (TTM)	-€35.98m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-2.6x

P/E Ratio

Is 47N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
47N income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$39.77m
Earnings	-US$39.77m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.22
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 47N perform over the long term?

See historical performance and comparison

47N Stock Overview

Rewards

Risk Analysis

Citius Pharmaceuticals, Inc. Competitors

DB:2FJ0

€92.8m

DB:93M1

€80.9m

DB:0RX

€65.0m

XTRA:APPH

€58.5m

Price History & Performance

Recent News & Updates

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

Recent updates

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

New major risk - Share price stability

The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2)

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir

New minor risk - Market cap size

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters

New minor risk - Profitability

Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR

Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial

Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Insufficient new directors

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Insufficient new directors

Citius Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Citius Pharmaceuticals, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2024

Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/Ontak (E7777)

Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Forecast breakeven date moved forward to 2023

Citius Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

Citius Pharmaceuticals, Inc. (NasdaqCM:CTXR) agreed to acquire Rights and Certain Related Assets of Dr. Reddy's Laboratories Limited (BSE:500124) for approximately $150 million.

Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned

Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial

Citius Pharmaceuticals, Inc. Reports Strong Clinical Community Engagement During Mino-Lok Phase 3 Trial-Related Webinar

Shareholder Returns

Price Volatility

About the Company

Citius Pharmaceuticals, Inc. Fundamentals Summary

0.0x

-2.6x

Earnings & Revenue